Literature DB >> 30477320

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals.

Chiara Macchi1, Nicola Ferri2, Chiara Favero3, Laura Cantone3, Luisella Vigna4, Angela C Pesatori3,4, Maria G Lupo2, Cesare R Sirtori5, Alberto Corsini1,6, Valentina Bollati3,4, Massimiliano Ruscica1.   

Abstract

AIMS: Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of cardiovascular disease. Obesity, one of the leading cardiovascular disease risk factors, increases susceptibility to the adverse effects of particulate matter exposure. Proprotein convertase subtilisin/kexin type 9 has been related to a large number of cardiovascular risk factors, e.g. atherogenic lipoproteins, arterial stiffness and platelet activation. Thus, the present study was aimed at evaluating, in a series of obese individuals, the effects of particulate matter less than 10 µm in diameter (PM10) on proprotein convertase subtilisin/kexin type 9 circulating levels. METHODS AND
RESULTS: In 500 obese subjects, participating in the cross-sectional Susceptibility to Particle Health Effects, miRNAs and Exosomes (SPHERE) study, we evaluated the effects of long- and short-term PM10 exposure on circulating proprotein convertase subtilisin/kexin type 9 levels. In the studied individuals (body mass index: 33.3 ± 5.2 kg/m2) with an annual average PM10 exposure of 40.12 ± 4.71 µg/m3, proprotein convertase subtilisin/kexin type 9 levels were 248.7 ± 78.6 ng/mL. In univariate analysis, PM10 exposure (annual average) was associated with proprotein convertase subtilisin/kexin type 9 levels (β=1.83, standard error = 0.75, p = 0.014). Interestingly, in a multivariable linear regression model, this association was observed only for carriers of lower concentrations of interferon-γ, whereas it was lost in the presence of higher interferon-γ levels. Proprotein convertase subtilisin/kexin type 9 levels were positively associated with the Framingham Risk Score, which was raised by 15.8% for each 100 ng/ml rise of proprotein convertase subtilisin/kexin type 9.
CONCLUSIONS: In obese individuals, more sensitive to the damaging effects of environmental air pollution, PM10 exposure positively associates with proprotein convertase subtilisin/kexin type 9 plasma levels especially in those with low levels of interferon-γ.

Entities:  

Keywords:  Air pollution; Framingham Risk Score; particular matter; proprotein convertase subtilisin/kexin type 9

Year:  2018        PMID: 30477320     DOI: 10.1177/2047487318815320

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  11 in total

Review 1.  Clinical approach to the inflammatory etiology of cardiovascular diseases.

Authors:  Massimiliano Ruscica; Alberto Corsini; Nicola Ferri; Maciej Banach; Cesare R Sirtori
Journal:  Pharmacol Res       Date:  2020-05-20       Impact factor: 7.658

2.  PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation.

Authors:  Elena Dozio; Massimiliano Ruscica; Elena Vianello; Chiara Macchi; Clementina Sitzia; Gerd Schmitz; Lorenza Tacchini; Massimiliano M Corsi Romanelli
Journal:  Mediators Inflamm       Date:  2020-06-04       Impact factor: 4.711

3.  Fine particulate matter (PM2.5) inhalation-induced alterations in the plasma lipidome as promoters of vascular inflammation and insulin resistance.

Authors:  Bradford G Hill; Benjamin Rood; Amanda Ribble; Petra Haberzettl
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-05       Impact factor: 4.733

4.  Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity.

Authors:  Chiara Macchi; Maria Francesca Greco; Chiara Favero; Laura Dioni; Laura Cantone; Mirjam Hoxha; Luisella Vigna; Giulia Solazzo; Alberto Corsini; Maciej Banach; Angela C Pesatori; Valentina Bollati; Massimiliano Ruscica
Journal:  Front Cardiovasc Med       Date:  2022-01-07

5.  NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.

Authors:  Jia Peng; Ming-Ming Liu; Jing-Lu Jin; Ye-Xuan Cao; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Qian Dong; Jing Sun; Rui-Xia Xu; Jian-Jun Li
Journal:  Lipids Health Dis       Date:  2022-01-07       Impact factor: 3.876

6.  Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease.

Authors:  Álvaro Petersen-Uribe; Marcel Kremser; Anne-Katrin Rohlfing; Tatsiana Castor; Kyra Kolb; Valerie Dicenta; Frederic Emschermann; Bo Li; Oliver Borst; Dominik Rath; Karin Anne Lydia Müller; Meinrad Paul Gawaz
Journal:  Int J Mol Sci       Date:  2021-10-16       Impact factor: 5.923

7.  Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors.

Authors:  Min-Tao Gai; Dilare Adi; Xiao-Cui Chen; Fen Liu; Xiang Xie; Yi-Ning Yang; Xiao-Ming Gao; Xiang Ma; Zhen-Yan Fu; Yi-Tong Ma; Bang-Dang Chen
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

Review 8.  Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis.

Authors:  Emily Punch; Justus Klein; Patrick Diaba-Nuhoho; Henning Morawietz; Mahdi Garelnabi
Journal:  J Am Heart Assoc       Date:  2022-01-20       Impact factor: 6.106

9.  NLRP3 inflammasome via IL-1β regulates PCSK9 secretion.

Authors:  Zufeng Ding; Xianwei Wang; Shijie Liu; Sichang Zhou; Rajshekhar A Kore; Shengyu Mu; Xiaoyan Deng; Yubo Fan; Jawahar L Mehta
Journal:  Theranostics       Date:  2020-05-30       Impact factor: 11.600

10.  Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance.

Authors:  C Macchi; C Favero; A Ceresa; L Vigna; D M Conti; A C Pesatori; G Racagni; A Corsini; N Ferri; C R Sirtori; M Buoli; V Bollati; M Ruscica
Journal:  Cardiovasc Diabetol       Date:  2020-11-03       Impact factor: 8.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.